Full Press Release Details
EXTON, Pa. , Feb. 1, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST ), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2023 financial results before the market opens on Thursday, February 15, 2024 , and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time .
The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here .
To participate in the conference call by asking questions to Management, please register in advance by clicking here . Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call.
Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company's website. A replay of the conference call and webcast will be available on the Company's website for 30 days.
A live audio webcast will be available in the "Investors" section of the Company's website at www.westpharma.com . Replay of the webcasts will be available for approximately 90 days after the events.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year.
In 2023, West commemorated a century of groundbreaking innovation that has shaped the landscape of healthcare and impacted the lives of patients around the world. This milestone served as a testament to West's commitment to revolutionize drug delivery and enhance the overall patient experience. Headquartered in Exton, Pennsylvania , West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST ) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com .
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.